Corza Medical Completes Acquisition of TachoSil Manufacturing Operations

Corza Medical completes acquisition of TachoSil production facilities in Linz, Austria

WESTWOOD, Mass., July 1, 2024 (GLOBE NEWSWIRE) — Medical Corza successfully completed the previously announced acquisition of the TachoSil production plant in Linz, Austria, which is part of the Takeda global production network. TachoSil is a best-in-class surgical plaster trusted by doctors around the world.

Corza Medical has taken over Commercial rights for TachoSil in January 2021. The acquisition of the manufacturing business will enable Corza Medical to continue to deliver exceptional value to its customers by combining operational excellence with a commercial excellence engine. It will also give the company direct control over manufacturing priorities, accelerating service levels and support for customers worldwide.

“The acquisition of TachoSil’s manufacturing operations represents an important milestone for Corza Medical. We are pleased to have successfully completed the acquisition and welcome the employees transitioning from Takeda,” he said Tomek TestaCEO of Corza Medical. “This acquisition will enable us to enhance our product offering and better serve our customers. We are committed to investing in TachoSil to improve patient care and deliver innovative solutions to surgeons worldwide.”

Chairman of the Board Gregory T. Lucer Corza Medical added: “The investment in having TachoSil manufacturing facilities in Linz will help streamline our supply chain and build stronger operational capabilities for our biosurgical business. We are confident that with the Linz facilities as part of our operations, we will enhance support for our customers and further deliver on the Corza brand promise of exceptional service, trusted performance and exceptional value to meet the needs of healthcare professionals.”

“By taking responsibility for the entire manufacturing process, we will be able to accelerate our growth, expand our manufacturing capacity and serve new countries. We are excited to improve patient care around the world,” he said. Thierry Leclercq Vice President of Corza Medical, GM Biosurgery.

Corza Medical is a portfolio company of GTCR, a leading private equity firm that helped create and build the company in partnership with Gregory T. Lucier. With a focused commitment to extraordinary service, trusted performance and exceptional economic value for customers, Corza Medical has the experience and resources to continue to invest in TachoSil for the benefit of its surgeons, partners and patients around the world.

About Corza Medical
Corza Medical is a leading global manufacturer of innovative surgical technologies. With a global team of more than 3,000 employees supporting physicians, distributor partners and medical device companies worldwide, Corza provides healthcare professionals with a surgical technology platform with many industry-leading brands, including Quill^® barbed seams, Sharpoint^® Plus and Look™ surgical sutures, Katena^® reusable and single-use Blink™ ophthalmic instruments, Barron corneal transplant devices, Sharpoint^® microsurgical knives and TachoSil^® fibrin sealing patch. For more information, visit www.corza.com.

About OWTR
Founded in 1980, GTCR is a leading private equity firm that pioneered The Leaders Strategy™ – finding and partnering with management leaders in key domains to identify, acquire and build market-leading companies through organic growth and strategic acquisitions. GTCR focuses on investing in the transformational growth of companies in the business and consumer services, financial services and technology, healthcare and technology, media and telecommunications sectors. Since its inception, GTCR has invested over $25 billion in over 270 companies, and the company currently manages over $40 billion of equity capital. GTCR is headquartered in Chicago with offices in New York and West Palm Beach. For more information, visit the website www.gtcr.com. Follow us on LinkedIn.

The story continues

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3b1335ed-d9ff-41b3-8bfa-81535087cd22

CONTACT: Media Contact Luci Curi—Director, Communications and PR [email protected]